Select Bibliography

Filter by any of these (after searching):

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 2 items

Daratumumab (DARA) + Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple MyNewly diagnosed multiple myeloma, daratumumab, autologous stem cell transplanteloma (NDMM): Final Analysis of GRIFFIN

Sborov, Douglas W. , Laubach, Jacob , Kaufman, Jonathan L. ... - IMS - - 2022

Abstract - No-Endpoint - Other - Myeloma - AFT-29 (GRIFFIN)

Addition of ixazomib to pomalidomide-dexamethasone improves progression-free survival for myeloma patients progressing on frontline lenalidomide: results of the randomized alliance study A061202

Voorhees, Peter , Suman, Vera , Efebera, Yvonne , Raje, Noopur ... - IMS - Clinical Lymphoma, Myeloma & Leukemia - 2022

Abstract - Primary - Primary - Myeloma - Alliance-A061202